Christine Esau PhD

Dr. Esau led the anti-miR-33 program for atherosclerosis which came out of these efforts and was the basis for Regulus’ partnership with Astra-Zeneca. While Chief Scientific Officer of AptamiR Therapeutics, Dr. Esau worked to develop a microRNA based therapy for the treatment of obesity. Dr. Esau earned a B.S. degree in biology from the California Institute of Technology and a Ph.D. from the Massachusetts Institute of Technology.